Real-time enrollment status for this diffuse midline glioma, h3 k27m-mutant clinical trial
Current Status
Recruiting
Checked: July 19, 2026 at 10:19 PM UTC
| NCT Number | NCT06305910 |
| Recruiting Status | Recruiting |
| Condition | Diffuse Midline Glioma, H3 K27M-Mutant |
| Phase | PHASE1 |
| Target Enrollment | 24 participants |
| Active Locations | 1 sites in the US |
| Sponsor | OX2 Therapeutics |
| Last Updated on CT.gov | March 12, 2024 (Mar 12, 2024) |
As of July 19, 2026: Clinical trial NCT06305910 is currently recruiting participants. This phase1 study for diffuse midline glioma, h3 k27m-mutant is actively seeking new participants at 1 location across the United States. The study is sponsored by OX2 Therapeutics. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06305910 is actively recruiting participants as of July 19, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06305910 was last updated Mar 12, 2024 (March 12, 2024). HelloStudys verifies this status automatically.